Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Narrative (Details)

v3.21.1
Summary of Significant Accounting Policies - Narrative (Details)
1 Months Ended 12 Months Ended 55 Months Ended
Apr. 28, 2020
USD ($)
Apr. 23, 2020
USD ($)
Jan. 07, 2020
USD ($)
Nov. 01, 2017
USD ($)
Jan. 31, 2020
shares
Dec. 31, 2019
USD ($)
Oct. 31, 2018
shares
Oct. 31, 2017
USD ($)
May 31, 2017
USD ($)
May 31, 2016
USD ($)
Dec. 31, 2020
USD ($)
segment
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
shares
Sep. 30, 2018
Dec. 31, 2017
Accumulated deficit           $ (104,597,748)         $ (130,647,485) $ (104,597,748) $ (130,647,485)    
Net loss                     (26,381,389) (20,384,716)      
Cash, cash equivalents and short term investments                     111,800,000   111,800,000    
Proceeds from PPP loan                     702,000        
Repayment of PPP loan                     $ 702,000        
Number of reportable segments | segment                     1        
Derivative warrant liability                     $ 33,779   33,779    
Cash balance insured           250,000         250,000 250,000 250,000    
Cash balance uninsured                     $ 10,367,714   $ 10,367,714    
Common stock issued in exchange for warrants (in shares) | shares                     319,756        
Warrants outstanding | shares                     9,357   9,357    
Fair value of the contingent consideration                     $ 1,199,000 613,290      
Goodwill gross           2,200,000           2,200,000      
Goodwill fair value           1,500,000           1,500,000      
Goodwill impairment loss                     0 737,000      
Unrecognized tax benefit           $ 0         $ 0 $ 0 $ 0    
Percentage of non-controlling interest acquired           15.00%         15.00% 15.00% 15.00%    
Revenue                     $ 2,947,969 $ 3,049,104      
Allowable expenses incurred under NIH grant                     $ 100,000        
Maximum                              
Aggregate public offering price   $ 150,000,000                          
Amount awarded from NIH grant     $ 224,713                        
Lab equipment                              
Useful life                     P5Y        
Computers                              
Useful life                     P3Y        
Furniture and fixtures                              
Useful life                     P8Y        
Leasehold Improvements                              
Useful life                     five        
Common stock warrants                              
Number of warrants reclassified to liability | shares         479,595                    
Warrants exchanged | shares                     470,238        
At The Market Offerings | Maximum                              
Percentage of commission fees to sales agent   3.00%                          
Heat I                              
Ownership interest in subsidiary             100.00%                
Pelican Therapeutics, Inc.                              
Ownership interest in subsidiary             85.00%             80.00%  
CPRIT                              
Grant receivable       $ 200,000                      
Deferred revenue       $ 600,000             $ 600,000   $ 600,000    
CPRIT | Minimum                              
Period of maintenance of employment levels       7 years                      
CPRIT | Grant revenue                              
Grant receivable                     1,500,000   1,500,000    
Heat I, Inc. and Pelican                              
Proceeds from PPP loan   $ 700,000                          
Repayment of PPP loan $ 700,000                            
Shares issued in acquisition | shares             35,000                
Pelican Therapeutics, Inc.                              
Percentage of non-controlling interest acquired                             20.00%
Amount awarded from CPRIT grant                   $ 15,200,000          
Contract value                     13,100,000        
Pelican Therapeutics, Inc. | Grant revenue                              
Revenue                         13,100,000    
Grant receivable                     $ 1,500,000   $ 1,500,000    
Pelican Therapeutics, Inc. | First tranche | Grant revenue                              
Revenue                 $ 1,800,000            
Pelican Therapeutics, Inc. | Second tranche | Grant revenue                              
Revenue               $ 6,500,000              
Pelican Therapeutics, Inc. | Third tranche | Grant revenue                              
Revenue           $ 5,400,000